Robert W. Baird analyst Brian Skorney maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report) on August 3 and set a price target of $110.00. The company's shares closed last Thursday at $101.45. According to TipRanks.com, Skorney is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -7.4% and a 42.8% success rate. Skorney covers the Healthcare sector, focusing on stocks such as Eiger Biopharmaceuticals, Vertex Pharmaceuticals, and Enanta Pharmaceuticals. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Sarepta Therapeutics with a $129.93 average price target, implying a 35.1% upside from current levels.
https://www.tipranks.com/news/blurbs/sarepta-therapeutics-srpt-gets-a-buy-rating-from-robert-w-baird-4?utm_source=advfn.com&utm_medium=referral
Sarepta Therapeutics (NASDAQ:SRPT)
Historical Stock Chart
From Aug 2022 to Sep 2022 Click Here for more Sarepta Therapeutics Charts.
Sarepta Therapeutics (NASDAQ:SRPT)
Historical Stock Chart
From Sep 2021 to Sep 2022 Click Here for more Sarepta Therapeutics Charts.